Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sage Therapeutic stock

Learn how to easily invest in Sage Therapeutic stock.

Sage Therapeutic is a biotechnology business based in the US. Sage Therapeutic shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutic employs 471 staff and has a trailing 12-month revenue of around $6.5 million.

How to buy Sage Therapeutic stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – SAGE. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Sage Therapeutic stock price (NASDAQ: SAGE)

Use our graph to track the performance of SAGE stocks over time.

Sage Therapeutic shares at a glance

Information last updated 2023-01-25.
Latest market close$44.51
52-week range$27.36 - $49.56
50-day moving average $39.67
200-day moving average $37.18
Wall St. target price$55.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-8.23

Buy Sage Therapeutic stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Sage Therapeutic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sage Therapeutic price performance over time

Historical closes compared with the close of $44.51 from 2023-01-25

1 week (2023-01-20) 4.57%
1 month (2022-12-27) 18.60%
3 months (2022-10-27) 19.27%
6 months (2022-07-27) 28.31%
1 year (2022-01-26) 17.91%
2 years (2021-01-27) -44.73%
3 years (2020-01-27) 67.32
5 years (2018-01-26) 183.47

Is Sage Therapeutic stock undervalued or overvalued?

Valuing Sage Therapeutic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sage Therapeutic's PEG ratio

Sage Therapeutic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sage Therapeutic financials

Revenue TTM $6.5 million
Gross profit TTM $-277,411,000
Return on assets TTM -18.99%
Return on equity TTM -31.74%
Profit margin 0%
Book value $23.20
Market capitalisation $2.7 billion

TTM: trailing 12 months

Sage Therapeutic share dividends

We're not expecting Sage Therapeutic to pay a dividend over the next 12 months.

Sage Therapeutic share price volatility

Over the last 12 months, Sage Therapeutic's shares have ranged in value from as little as $27.36 up to $49.56. A popular way to gauge a stock's volatility is its "beta".

SAGE.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutic's is 1.1353. This would suggest that Sage Therapeutic's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Sage Therapeutic overview

Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co.

Frequently asked questions

What percentage of Sage Therapeutic is owned by insiders or institutions?
Currently 12.524% of Sage Therapeutic shares are held by insiders and 88.915% by institutions.
How many people work for Sage Therapeutic?
Latest data suggests 471 work at Sage Therapeutic.
When does the fiscal year end for Sage Therapeutic?
Sage Therapeutic's fiscal year ends in December.
Where is Sage Therapeutic based?
Sage Therapeutic's address is: 215 First Street, Cambridge, MA, United States, 02142
What is Sage Therapeutic's ISIN number?
Sage Therapeutic's international securities identification number is: US78667J1088
What is Sage Therapeutic's CUSIP number?
Sage Therapeutic's Committee on Uniform Securities Identification Procedures number is: 78667J108

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site